Screening for cystic fibrosis

INSTRUCTIONS Screening for cystic fibrosis: What every NP should know TEST INSTRUCTIONS To take the test online, go to our secure website at http://www.nursingcenter.com/ce/NP. On the print form, record your answers in the test answer section of the CE enrollment form on page 33. Each question has only one correct answer. You may make copies of these forms. Complete the registration information and course evaluation. Mail the completed form and registration fee of $24.95 to: Lippincott Williams & Wilkins, CE Group, 74 Brick Blvd., Bldg. 4, Suite 206, Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form. You will receive your CE certificate of earned contact hours and an answer key to review your results.There is no minimum passing grade. Registration deadline is September 30, 2015. DISCOUNTS and CUSTOMER SERVICE Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together and deduct $0.95 from the price of each test. We also offer CE accounts for hospitals and other healthcare facilities on nursingcenter.com. Call 1-800-787-8985 for details. PROVIDER ACCREDITATION Lippincott Williams & Wilkins, publisher of The Nurse Practitioner journal, will award 2.8 contact hours for this continuing nursing education activity. Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2.8 contact hours. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #50-1223. Your certificate is valid in all states. The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing educational activities and does not imply Commission on Accreditation approval or endorsement of any commercial product. Screening for cystic fibrosis: What every NP should know General Purpose: The purpose of this learning activity is to provide information about advances in the screening and diagnosis of patients with CF. Learning Objectives: After reading this article and taking this test, you will be able to: 1. Explain the diagnosis of CF by way of screening mechanisms and signs and symptoms. 2. Identify the mutations associated with CF. 3. List other conditions associated with CF. The highest rate of newborn CF in the United States is among Blacks. Hispanic Americans. Whites. Asian Americans. Which statement about NBS programs is accurate? They have been adopted by all 50 states and the District of Columbia. They are not available in the United States, but are used internationally. All states use the same protocol. If the screening results are negative, CF can be ruled out as a diagnosis. CF is defined as an autosomal dominant disease. an inherited genetic disorder. the absence of chromosome 7. excessive transport of chloride across cell membranes. Individuals typically express symptoms of CF if they have a single mutation from both groups B and C. one mutation from group D. two mutations. any mutation from group C. The more severe mutations of the CFTR gene are from Class I-III. Class C and D. Class IV and V. Class III and V. The most severe CF-causing genotype is Class III mutations. two ΔF508 mutations. Class V mutations. groups B and D mutations. Which body site is generallynot affected by the gene mutations of CF? vas deferens sweat glands liver kidneys The primary cause of 90% of all CF deaths is electrolyte imbalance. respiratory infection. lung deterioration. malnutrition. Altered secretion of bicarbonate and pancreatic enzymes can cause vitamin deficiencies. insulin resistance. excessive secretion of insulin. excessive secretion of bicarbonate. CF-related liver disease is caused by focal biliary cirrhosis multilobular cirrhosis. failure of the liver's endocrine cells to function properly. thickening of gallbladder bile resulting in obstruction. The electrolytes released by the sweat glands of CF patients create risk for hypernatremia. include large amounts of sodium and chloride. is associated with infertility in males. cause excessive sodium uptake in epithelial membranes. Frequency of CF carriers in the United States is lowest among Ashkenazi Jews. Blacks. Asian Americans. Hispanic Americans. Prenatal testing of known carriers includes a selective panel of the 25 most common mutations. a chorionic villus sample at 11 weeks. amniocentesis at 18 weeks. in vitro fertilization embryo screening prior to implantation. The percentage of CFTR mutations undetected in genetic testing of patients diagnosed with CF is 0%. 1% to 5%. 6% to 10%. 12% to 15%. A clinical sign of CF in a newborn is excessive sweat production. reduced neurologic responses. hyponatremia. meconium ileus. The gold standard diagnostic test for CF is the IRT/DNA analysis. CFTR mutation screening. the sweat test. the IRT/IRT protocol. Growth in CF patients has improved with a diet low in fat and high in calories. high in fat and calories. low in salt with enzyme supplements. reduced in protein and high in calories. Early signs and symptoms of CF include all of the followingexcept hemoptysis. constipation. anemia. failure to sweat when spiking a fever.